By Robb M. Stewart

Appili Therapeutics expects to receive milestone payments and royalties from Saptalis Pharmaceuticals after the U.S. Food and Drug Administration approved the liquid oral reformulation of the antibiotic metronidazole, which has been licensed to Saptalis for commercialization in the U.S. and other select markets.

The biopharmaceutical company said Saptalis received FDA approval for ATI-1501, metronidazole oral suspension 500 milligram. The FDA also approved Likmez as the brand name for ATI-1501.

Don Cilla, president and chief executive of Appili, said the approval of Likmez shortly after patent coverage was secured through 2039 demonstrates the company's ability to identify promising opportunities and develop and monetize them for the benefit of patients and shareholders.

Write to Robb M. Stewart at robb.stewart@wsj.com

(END) Dow Jones Newswires

September 25, 2023 08:29 ET (12:29 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Appili Therapeutics (TSX:APLI)
過去 株価チャート
から 4 2024 まで 5 2024 Appili Therapeuticsのチャートをもっと見るにはこちらをクリック
Appili Therapeutics (TSX:APLI)
過去 株価チャート
から 5 2023 まで 5 2024 Appili Therapeuticsのチャートをもっと見るにはこちらをクリック